HOTH
Hoth Therapeutics Inc

11,562
Mkt Cap
$17.84M
Volume
1.94M
52W High
$3.80
52W Low
$0.6554
PE Ratio
-1.08
HOTH Fundamentals
Price
$1.03
Prev Close
$1.15
Open
$1.20
50D MA
$1.50
Beta
0.98
Avg. Volume
922,378.96
EPS (Annual)
-$1.28
P/B
2.11
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and...
PR Newswire·10h ago
News Placeholder
More News
News Placeholder
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy...
PR Newswire·24d ago
News Placeholder
Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical...
PR Newswire·1mo ago
News Placeholder
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting...
PR Newswire·9mo ago
News Placeholder
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements PR Newswire NEW YORK, Jan. 24, 2025 NEW YORK, Jan. 24, 2025...
PR Newswire·10mo ago
News Placeholder
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent...
PR Newswire·10mo ago
News Placeholder
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 PR Newswire NEW YORK, Jan. 17, 2025 NEW YORK, Jan. 17...
PR Newswire·10mo ago
News Placeholder
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries PR Newswire NEW YORK, Jan. 8, 2025 The Company affirms...
PR Newswire·11mo ago
News Placeholder
Hoth Therapeutics’ Stock Triples On Promising Cancer Trial Data for Skin Toxicity Therapy: Retail’s Excited
The trial achieved a 100% success rate for its primary efficacy endpoint, with all patients showing significant improvement in skin toxicities within six weeks.
Stocktwits·11mo ago
News Placeholder
Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities
Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001...
PR Newswire·11mo ago

Latest HOTH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.